Akari Therapeutics, Plc AKTX
$ 0.98
-2.5%
Quarterly report 2024-Q3
added 12-21-2024
Akari Therapeutics, Plc Balance Sheet 2011-2024 | AKTX
Annual Balance Sheet Akari Therapeutics, Plc
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | - | - | - | - | -5.45 M | -28.1 M | -34.1 M | -68.9 M | -6.22 M | -7.66 M | -206 K | -6 K | |
Long Term Debt |
- | - | - | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
- | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | 50 K | 60 K | 50 K | 268 K | 787 K | 630 K | 276 K |
Total Current Liabilities |
24 M | 20.5 M | 10.8 M | - | - | - | - | - | 11.7 M | 21.1 M | 1.36 M | 1.23 M | 3.85 M | - |
Total Liabilities |
24 M | 20.8 M | 15.6 M | 6.09 M | 5.22 M | 8.57 M | 4.92 M | 11.9 M | 11.8 M | 21.2 M | 1.63 M | 2.02 M | 4.48 M | 2.51 M |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-42.7 M | -38.2 M | -25.3 M | -200 M | -182 M | -144 M | -127 M | -110 M | -74.9 M | -56.8 M | -30.2 M | -20.5 M | -16.9 M | -12.6 M |
Total Assets |
1.43 M | 2.6 M | 7.53 M | 11.6 M | 14.6 M | 6.8 M | 8.03 M | 29 M | 45.9 M | 69.9 M | 6.48 M | 7.83 M | 1.12 M | 27 K |
Cash and Cash Equivalents |
- | 3.84 M | 13.2 M | - | 14.1 M | 5.73 M | 5.45 M | 28.1 M | 34.1 M | 68.9 M | 3.33 M | 554 K | 1.1 M | 6 K |
Book Value |
-22.6 M | -18.2 M | -8.09 M | 5.55 M | 9.38 M | -1.77 M | 3.11 M | 17.2 M | 34.1 M | 48.7 M | 4.85 M | 5.81 M | -3.36 M | -2.48 M |
Total Shareholders Equity |
-22.6 M | -18.2 M | -8.09 M | -1.94 M | 9.38 M | 7.6 K | 3.11 M | 17.2 M | 34.1 M | 48.7 M | 2.22 M | 401 K | -3.36 M | -2.48 M |
All numbers in USD currency
Quarterly Balance Sheet Akari Therapeutics, Plc
2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 213 K | - | 48 K | - | 58 K | - | 56.4 K | - | 55.1 K | 52.1 K | 49.1 K | 46 K | 1.03 M | 49.1 K | - | - | 268 K | 268 K | 787 K | - | - | - | 630 K | - | - | - | 276 K | - | - | - |
Total Liabilities |
- | - | - | - | - | - | - | - | - | - | - | 6.09 M | - | 3.24 M | - | 5.22 M | 6.75 M | 8.49 M | 6.41 M | 6.47 M | 5.37 M | 4.15 M | 3.39 M | 4.92 M | - | 8.49 M | - | 11.9 M | - | 9.2 M | - | 11.8 M | - | 17 M | 16.6 M | 21.2 M | 37.8 M | - | 21.2 M | 1.17 M | 1.17 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-243 M | -241 M | -233 M | -227 M | - | - | - | - | - | - | - | -200 M | - | -192 M | - | -182 M | -175 M | -176 M | -169 M | -165 M | -157 M | -154 M | -149 M | -127 M | - | -120 M | - | -110 M | - | -87.8 M | - | -74.9 M | - | -66.2 M | -59.8 M | -56.8 M | -63.3 M | -34.2 M | -56.8 M | -11.5 M | -11.5 M | -30.2 M | -30.2 M | -20.5 M | - | - | - | -16.9 M | - | - | - | -12.6 M | - | - | - |
Total Assets |
2.73 M | 5.08 M | 2.77 M | 4.36 M | - | - | - | - | - | - | - | 11.6 M | - | 4.83 M | - | 14.6 M | 13.7 M | 14.5 M | 9.68 M | 6.48 M | 10.3 M | 4.61 M | 8.23 M | 8.03 M | - | 17.1 M | - | 29.1 M | - | 32.1 M | - | 45.9 M | - | 57.6 M | 63 M | 69.9 M | 79.2 M | 2.96 M | 69.9 M | 3.39 M | 3.39 M | 6.48 M | 6.48 M | 7.83 M | - | - | - | 1.12 M | - | - | - | 27 K | - | - | - |
Cash and Cash Equivalents |
2.25 M | 4.18 M | 1.31 M | 3.84 M | 4.73 M | 7.18 M | 11.6 M | - | - | - | - | 9.36 M | - | 3.79 M | - | 14.1 M | 12.3 M | 12.7 M | 7.82 M | 5.73 M | 6.27 M | 2.74 M | 6.15 M | 5.45 M | - | 15.1 M | - | 28.1 M | - | 30.1 M | - | 34.1 M | - | 9.66 M | 61.4 M | 68.9 M | 78.8 M | 201 K | 68.9 M | 3.33 M | 3.33 M | 6.22 M | 6.22 M | 554 K | - | - | - | 1.1 M | - | - | - | 6 K | - | - | - |
Book Value |
- | - | - | - | - | - | - | - | - | - | - | 5.55 M | - | 1.59 M | - | 9.38 M | 6.95 M | 5.96 M | 3.27 M | 7.6 K | 4.9 M | 459 K | 4.84 M | 3.11 M | - | 8.63 M | - | 17.2 M | - | 22.9 M | - | 34.1 M | - | 40.6 M | 46.4 M | 48.7 M | 41.3 M | 2.96 M | 48.7 M | 2.22 M | 2.22 M | 6.48 M | 6.48 M | 7.83 M | - | - | - | 1.12 M | - | - | - | 27 K | - | - | - |
Total Shareholders Equity |
-6.69 M | -3.7 M | -3.55 M | -229 K | 213 K | 2.78 M | 6.56 M | - | - | - | - | 5.55 M | - | 1.59 M | 3.94 M | 9.38 M | 6.95 M | 5.96 M | 3.27 M | 7.6 K | 4.9 M | 459 K | 4.84 M | 4.37 M | - | 8.63 M | 16.3 M | 22.2 M | - | 22.9 M | - | 34.1 M | - | 40.6 M | 46.4 M | 48.7 M | 41.3 M | 973 K | 48.7 M | 2.22 M | 2.22 M | 4.85 M | 4.85 M | 401 K | - | - | - | -3.36 M | - | - | - | -2.48 M | - | - | - |
All numbers in USD currency